The OTT166-201 Study

A phase 2 randomized, double-masked, vehicle controlled, multicenter study to evaluate the safety and efficacy of OTT166 ophthalmic solution in the treatment of diabetic retinopathy.

This study evaluates the safety and effectiveness of OTT166, an eye drop intended to treat patients with diabetic retinopathy. Patients who had moderately severe to severe non-proliferative or moderately proliferative diabetic retinopathy were enrolled. The study duration is 24 weeks long.

Explore Our Active Trials

  • The Izervay Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an…

  • The ASP7317 Study

    July 23, 2026

    Sponsor: Astellas Trial Summary Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina – the light-sensitive part at the back of the eye. There are 2 types of…

  • The EVOLVE Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is focused on people with Stargardt disease (STGD) and STGD-like macular dystrophies, inherited retinal conditions that affect the macula and can lead to progressive loss of central vision. STGD is most commonly caused by changes in the ABCA4 gene, while STGD-like conditions are linked…

  • The SIENNA Study

    July 22, 2026

    Sponsor: REGENERON Trial Summary This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition…